Tango Therapeutics
Coverage of Tango Therapeutics in the Nexus archive.
- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
A clinical trial showed improved outcomes for pancreatic cancer patients using a combination of Tango Therapeutics' PRMT5 inhibitor and Revolution Medicines' pan-RAS inhibitor. The article speculates on potential biotech mergers and acquisitions involving companies like Revolution Medicines, Tango Therapeutics, and Bristol Myers Squibb.
- Tango Therapeutics stock surges on pancreatic cancer drug combo data
Tango Therapeutics' stock surged after a combination of vopimetostat and Revolution Medicines' daraxonrasib showed a 92% response rate in patients with advanced pancreatic cancer.
- Tango Soars as Study Shows Its Drug Can Help Shrink Tumors
A study indicates that Tango Therapeutics' drug can help shrink tumors, leading to the company's stock surge. The findings suggest potential therapeutic benefits for cancer treatment.
- STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib showed durable responses in most pancreatic cancer patients in an early-stage trial. Revolution's drug has demonstrated unprecedented outcomes, highlighting potential in oncology treatments.